Tags

Type your tag names separated by a space and hit enter

Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development.
J Infect Dis. 2020 06 29; 222(2):180-182.JI

Links

PMC Free PDF

Authors+Show Affiliations

Graepel KW
Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Kochhar S
Global Healthcare Consulting, New Delhi, India. Department of Global Health, Schools of Medicine and Public Health, University of Washington, Seattle, Washington, USA.
Clayton EW
Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Center for Biomedical Ethics and Society and Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. Vanderbilt University Law School, Nashville, Tennessee, USA.
Edwards KE
Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

MeSH

AnimalsAntibodies, NeutralizingAntibodies, ViralAntibody-Dependent EnhancementBetacoronavirusCOVID-19COVID-19 VaccinesClinical Trials as TopicCoronavirus InfectionsHumansImmunogenicity, VaccinePandemicsPneumonia, ViralSARS-CoV-2Viral Vaccines

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32365191

Citation

Graepel, Kevin W., et al. "Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development." The Journal of Infectious Diseases, vol. 222, no. 2, 2020, pp. 180-182.
Graepel KW, Kochhar S, Clayton EW, et al. Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development. J Infect Dis. 2020;222(2):180-182.
Graepel, K. W., Kochhar, S., Clayton, E. W., & Edwards, K. E. (2020). Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development. The Journal of Infectious Diseases, 222(2), 180-182. https://doi.org/10.1093/infdis/jiaa234
Graepel KW, et al. Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development. J Infect Dis. 2020 06 29;222(2):180-182. PubMed PMID: 32365191.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development. AU - Graepel,Kevin W, AU - Kochhar,Sonali, AU - Clayton,Ellen W, AU - Edwards,Kathryn E, PY - 2020/04/26/received PY - 2020/04/30/accepted PY - 2020/5/5/pubmed PY - 2020/7/8/medline PY - 2020/5/5/entrez SP - 180 EP - 182 JF - The Journal of infectious diseases JO - J Infect Dis VL - 222 IS - 2 SN - 1537-6613 UR - https://www.unboundmedicine.com/medline/citation/32365191/Balancing_Expediency_and_Scientific_Rigor_in_Severe_Acute_Respiratory_Syndrome_Coronavirus_2_Vaccine_Development_ DB - PRIME DP - Unbound Medicine ER -